IGL Group has acquired Celsior®
The IGL Group, based in France, has acquired Celsior® from Sanofi Genzyme for US$11.5 million.
Companies within the IGL Group develop research programmes that have led to the development of products designed specifically to improve organ recovery, preservation, transport and evaluation systems before transplant. The IGL-1® preservation solution is particularly well suited for expanded criteria donors.
Celsior®, producing liquid compositions for perfusion, reperfusion and preservations of organs, is part of the Sanofi Genzyme group, a global healthcare leader focused on the research, development, manufacturing and marketing of innovative therapeutic solutions.
Sanofi Genzyme is engaged in the research, development, manufacturing and marketing of innovative therapeutic solutions. Sanofi's core strength is in the healthcare sector, with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme.
Oaklins' team in France advised the buyer in this transaction.
Talk to the deal team
Related deals
Instituto Sanitas and Chemopharma have been acquired by Laboratorios Saval
Instituto Sanitas and Chemopharma, leading pharmaceutical laboratories in Chile, have been acquired by Laboratorios Saval S.A., a prominent pharmaceutical company based in Chile with a regional presence across Latin America. The transaction strengthens Laboratorios Saval’s growth strategy and supports its expansion in the affordable medicines segment.
Learn moreRare Patient Voice has been acquired by Konovo
Rare Patient Voice has been acquired by Konovo, a technology-first healthcare intelligence company backed by Fraser Healthcare Partners.
Learn moreLindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.
Learn more